ESTRO 2024 - Abstract Book

S277

Brachytherapy - Gynaecology

ESTRO 2024

A total of 363 hybrid IGBT procedures in 92 patients were performed between January 2014 and December 2022. The median follow-up time was 39 (IQR, 22–61) months. The patient and tumour characteristics are summarised in Table 1. The median overall treatment time was 51 (IQR, 49–56) days.

Table 1: Patient and tumour characteristics

All patients underwent intracavitary (IC) and interstitial (IS) BT with needles (median, 9; range, 2-22). The mean + standard deviation HRCTV volume was 39 + 15 cm3, and the HRCTV D90 dose was 91 + 5 Gy. The 2 cm3 to the bladder and rectum were 85 + 6 Gy and 68 + 5.5 Gy, respectively. Only three patients developed local failure. 3 year local and locoregional relapse-free survival were 97.7% and 88.4%, respectively. The estimated progression free survival and overall survival for the entire population were 79.4% and 87.1%, respectively. Twenty-six (82%) patients who developed disease progression had salvage treatment. Eleven patients (12%) had grade 2 proctitis, but no grade 3 proctitis was reported. Two patients (2.2%) had grade 2 cystitis, and one patient (1.1%) had grade 3 urethral stricture. No patients had > grade 4 toxicity. No brachytherapy-related complications such as bleeding, infection, vaginal lacerations, or uterine perforation were reported.

Conclusion:

Combined IC/IS brachytherapy for LACC allows for recommended doses to achieve local control even in large tumours after chemoradiotherapy, improving target volume coverage with low rates of toxicities. Hybrid IGBT technique is essential to have a favourable scenario at the time of brachytherapy to correctly treat locally advanced cervical cancer patients.

Keywords: IGBT, cervix cancer, HRCTV

2811

Digital Poster

Two brachytherapy techniques for the management of lower third vaginal involvement in cervix cancer